Pacira | PCRX - Gross Profit On Sales


Pacira reported $133.91M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Astellas Pharma JPY 482.54B 38.28B Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Coherus Biosciences USD 8.7M 853K Dec/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
J&J USD 18.55B 1.31B Jun/2026
Ligand Pharmaceuticals USD 100.41M 51.96M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Omeros USD -33.16M 18.52M Jun/2024
Pacira USD 133.91M 7.27M Jun/2026
Perrigo USD 313.9M 11.6M Jun/2026
Pfizer USD -248M 11.29B Jun/2026
Supernus Pharmaceuticals USD 160.06M 30.7M Jun/2026
Teva Pharmaceutical Industries USD 2.15B 45M Jun/2026
Xeris Pharmaceuticals USD 72.55M 404K Mar/2026
Zoetis USD 1.76B 140M Jun/2026